Post hoc analyses of the AREDS / AREDS2 studies presented at the recent American Academy of Ophthalmology meeting examined ...

The Norse Eight trial was part of the data requested by the FDA after the agency rejected the BLA for the company’s Lytenava ...

Outlook said it remains confident that ONS-5010, marketed as Lytenava in the EU, is an important therapy for the treatment of wet age-related macular degeneration in place of off-label repackaged ...

Outlook Therapeutics’ eye disease drug has failed to match Roche’s Lucentis in a key trial. The biotech brushed off the ...

In the NORSE EIGHT trial, ONS-5010 did not meet the pre-specified non-inferiority endpoint at week 8 set forth in the special protocol assessment (SPA) with the U.S. Food and Drug Administration (FDA) ...

Outlook Therapeutics (OTLK) stock plunges 81% after clinical trial failure for its wet AMD therapy, ONS-5010. Read more here.

In a study, a team of Korean researchers developed an AI model using OCT images to predict neovascular AMD treatment outcomes after anti-VEGF injections. The model highlights AI’s potential in ...

Opthea Limited Sponsored ADR (OPT) has released an update.Don't Miss our Black Friday Offers:Unlock your investing potential with TipRanks ...

With essential nutrients, you can maintain good eye health. Try these fruits and vegetables -- among other foods -- for ...

The Dover Low Vision group will be meeting at The Central Hall Commons, 152 East Main Street, from 10-11:30 a.m.

Findings from a post hoc analysis of the AREDS and AREDS2 studies were presented at the recent American Academy of ...

Asimov, the synthetic biology company advancing the design and manufacture of therapeutics, today announced a licensing agreement for its CHO Edge System with RevOpsis Therapeutics ("RevOpsis"), a nex ...